



Universität  
Basel

Wirtschaftswissenschaftliche  
Fakultät



# «Pharmaceutical Innovation, Drug Use and Health Outcomes»

Tuesday, June 7<sup>th</sup>, 2022



interpharmaph

Panel

# «Pharmaceutical Innovation, Drug Use and Health Outcomes»

Tuesday, June 7<sup>th</sup>, 2022 | 18.15 h - 19.45 h |  
WWZ Auditorium, Peter Merian-Weg 6, Basel

## Programm

18:15 **Introduction**

Prof. Stefan Felder,  
University of Basel

18:20 **Premature Death and Hospital Utilization in Switzerland**

Prof. Frank R. Lichtenberg,  
Columbia University

18:45 **Off-label Drug Use and Disability: Evidence from the USA**

Prof. Katharina Blankart,  
Duisburg-Essen University

19:05 **Panel Discussion** with the speakers and Markus A. Ziegler, moderated by Stefan Felder

19:45 Apéro

## Abstract

Pharmaceutical innovation and the use of new drugs have contributed to the substantial decrease in mortality observed over the last decades. At the same time, there are potentially missed opportunities in the drug use for two reasons. First, older vintage drugs are still prescribed. Replacing them by new vintage drugs might further reduce mortality and increase patients' quality of life. Second, some drugs are used outside their designated labels for which scientific evidence is lacking or weak. The effect of off-label use on patient outcomes provides for a proxy of the potential efficiencies gained from targeted drug approvals and the role of biomedical innovation.

Please register before:

**June 2<sup>nd</sup>, 2022**

@ [forum-wwz@unibas.ch](mailto:forum-wwz@unibas.ch)

## Speakers | Panel Participants

### **Prof. Katharina Blankart**



Katharina Blankart is an assistant professor in empirical health economics at the Faculty of Business Administration and Economics of University of Duisburg-Essen. Her research covers innovation management, regulatory science and analysis of health care system performance. She is particularly interested in studying pharmaceutical markets and ambulatory care settings.

### **Prof. Frank R. Lichtenberg**



Frank R. Lichtenberg is Professor of Healthcare Management at the Columbia University Graduate School of Business and Research Associate of the National Bureau of Economic Research. Some of his research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He specially studied the impact of pharmaceutical innovation on longevity around the world.

### **Markus A. Ziegler**



Markus A. Ziegler is member of the executive board of interpharma, the association of Switzerland's research-based pharmaceutical industry. Prior joining interpharma Markus held various market access and corporate affairs roles of increasing responsibility in the bio-pharmaceutical industry. He started his career with the association of the health insurance companies where he served on the federal drug commission (EAK). Markus studied economics at the University of Basel.


### **Prof. Stefan Felder**



Stefan Felder is Full Professor at the Interpharma professorship of Health Economics. His research interests are in the regulation of health-care and health-insurance markets. Between 2011 and 2022 he was a member of the Swiss Medical Board. As a former member of a medical faculty, medical decision making has become one of his favorite fields.

via SBB  
Bahnhof Ausgang Innenstadt/City,  
nach rechts durch die Post-Passage,  
vorbei am Peter Merian-Haus (grün),  
zum Jacob Burckhardt Haus 6 (silberfarben)  
ca. 7 Gehminuten

Mit dem Tram Nr. 10 (Richtung Dornach)  
oder Tram Nr. 11 (Richtung Aesch) eine Station  
bis Haltestelle Peter Merian.



## Educating Talents since 1460.

Universität Basel  
Wirtschaftswissenschaftliche Fakultät  
WWZ Auditorium, Erdgeschoss  
Peter Merian-Weg 6  
4002 Basel  
Switzerland

[wwz.unibas.ch](http://wwz.unibas.ch)